Facebook
Twitter
LinkedIn
ForwardTitle
Category
Credits
Event date
Cost
- CMHC
- 1.50 AAFP
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Participation
$0.00
This interactive infographic covers a variety of topics surrounding the role of insulin therapy in type 2 diabetes (T2D) management, including practical pearls for initiation and maintenance of insulin therapy, how insulin therapy fits in with other T2D treatment options, and emerging insulin options. The information is presented in an interactive format, which contains a mix of high-impact visuals, infographics, expert faculty videos, as well as resources and suggested readings, all organized into different segments to facilitate learning.
- CMHC
- TME
- 0.75 ACPE Pharmacy
- 0.75 AMA PRA Category 1 Credit™
- 0.75 ANCC
- 0.75 Participation
$0.00
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects an estimated 25-30% of people in the United States and can often progress to Metabolic dysfunction-associated steatohepatitis (MASH) and cirrhosis. MASH represents a metabolic-driven array of multi-organ pathology that intersects with obesity, prediabetes, type 2 diabetes, and cardiovascular ailments. Many agents are currently in development for treatment of MASH, including glucagon-like peptide-1 receptor agonists (GLP1-Ras).
- CMHC
- 1.50 ACPE Pharmacy
- 1.50 AMA PRA Category 1 Credit™
- 1.50 ANCC
- 1.50 CDE
- 1.50 Participation
$0.00
Effectively and safely lowering LDL-C is essential to prevent and reduce the risk of recurrent ASCVD events. Despite advancements in LDL-C lowering therapies, achieving LDL-C targets remains suboptimal due to clinical inertia and patient non-adherence, contributing to patient's residual ASCVD risk. The landscape of LDL-C lowering therapies is rapidly evolving, with several new and emerging agents that may help bridge these gaps.
- LivDerm
- TME
- 1.00 AAPA Category I CME
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 Participation
$0.00
The management of AA in adolescents presents various challenges to dermatology professionals, including identification of AA, limited effective treatment options, and high disease burden. Because hair loss has a significant physical and psychological impact on a child’s development, early diagnosis and treatment are essential. Currently there is only one systemic therapy approved for adolescents; however, there are additional therapies on the horizon with promising data.
- LivDerm
- TME
- 0.75 AMA PRA Category 1 Credit™
- 0.75 ANCC
- 0.75 Participation
$0.00
Traditional treatments for seborrheic dermatitis, including oral and topical steroids, present a variety of challenges including lack of efficacy, adverse events with long-term use, limitations for adherence, and the inability to treat both hair- and non-hair-bearing areas. Recently, the first targeted therapy for treatment of seborrheic dermatitis, a PDE-4 inhibitor topical foam, was approved by the FDA.
- LivDerm
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 Participation
$0.00
Various gaps in the management of psoriasis in patients with SOC persist due to a lack of training for dermatology practitioners. As a result, patients with SOC are often misdiagnosed, experience more severe disease, and experience more disease burden. Given the predicted increase in the SOC population over the next decades, improving the diagnosis and management of psoriasis in these patients is critical.
Understanding the Role of Lp(a) as a CV Risk Marker to Therapeutic Target in the Prevention of ASCVD
- CMHC
- 1.50 ACPE Pharmacy
- 1.50 AMA PRA Category 1 Credit™
- 1.50 ANCC
- 1.50 CDE
- 1.50 Participation
$0.00
Residual ASCVD risk may be present even after the optimization of LDL-C levels and increasing evidence has suggested that elevated Lp(a) is an emerging CVD risk factor that has been shown to be a causal CVD risk factor in epidemiological and genetic studies, as well as enhance CVD risk prediction in certain patients. As emerging CVD risk factors, including Lp(a), are increasingly recognized as a target for therapy in the prevention and treatment of ASCVD, clinicians should be aware of the therapeutic advances in this field.
- CMHC
- 0.75 ACPE Pharmacy
- 0.75 AMA PRA Category 1 Credit™
- 0.75 ANCC
- 0.75 Participation
$0.00
Effectively managing high cholesterol level and safely lowering LDL-C is crucial for preventing and reducing the risk of adverse cardiovascular events. However, achieving LDL-C goals remains suboptimal, particularly in high-risk and very high-risk patients. The landscape of lipid lowering therapy has significantly evolved, with new consensus statements, newer agents, and important evidence that may help address some current gaps.
- LivDerm
- TME
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 Participation
$0.00
Various gaps in the management of psoriasis patients with skin of color (SOC) persist due to a lack of training on SOC and inherent barriers to care. As a result, psoriasis patients with SOC are often misdiagnosed, experience more severe disease, and experience more disease burden. Recent clinical trial data supports the need for nuanced care when treating psoriasis patients with SOC using systemic agents. It is important that clinicians are able to identify treatment barriers and develop strategies to address these barriers and personalize care.
- CMHC
- 0.50 ACPE Pharmacy
- 0.50 AMA PRA Category 1 Credit™
- 0.50 ANCC
- 0.50 CDE
- 0.50 Participation
$0.00
This Ace the Case Series is designed to be quick and offer high-level takeaways and pearls.Case #1: A 37-Year-Old Man with Incidental Hepatic Steatosis on Abdominal UltrasoundDuring this Ace the Case activity, you will learn about risk factors for metabolic dysfunction–associated steatotic liver disease (MASLD), metabolic dysfunction–associated steatohepatitis (MASH), and advanced fibrosis, as well as the current and emerging noninvasive liver assessment tests.